HPAP006 Donor Summary

HPAP	006	**UNOS**	
Recovery OPO	GLDP	**Allocation Via**	UPENN ☒ nPOD ☐
Age (years)	46	**DCD**	YES ☐ NO ☒
Race	Caucasian	**DBD**	YES ☒ NO ☐
Sex	M ☒ F☐	**Admission to Cross Clamp**	75 Hours 9 Mins.
ABO (Rh)	A+	**Cross Clamp Time**	03/02/2017 @ 16:06 EST.
BMI (Kg/m^2)	19.3	**Cold Ischemia Time***	17 Hours 1 Mins.
Cause of Death	CVA/Stroke	**Preservation Solution**	UW ☒ HTK☐
Mechanism of Injury	ICH	**Organs Recovered**	Heart ☐ Kidney ☒ Lung ☒ Pancreas ☒ Liver ☒ Intestine ☐
Cardiac Arrest/Downtime	Yes ☐ No ☒	**Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:**	0 Hours 22 Mins.
CPR / Time	Yes ☐ No ☒	**Organs Discarded**	Heart ☐ Kidney ☐ Lung ☐ Pancreas ☐ Liver ☐ Intestine ☐
Total Est. Downtime	None	**Blood Culture**	No Growth
Date /Time of Admission	02/27/2017 @22:57 EST	**PHS High Risk**	YES ☐ NO ☒
		Acute Lung Injury	No ARDS Aspiration pneumonia lower lobes

***Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.**

HPAP006 Donor Summary

Medical History:

		Duration	Medications	Compliance
Type of Diabetes	None	----------	----------	----------
History of cancer	None	----------	----------	----------
CAD	None	----------	----------	----------
Hypertension	Yes	2 years	Unknown Meds.	Yes
Hyperlipidemia	None	----------	----------	----------
Autoimmune disease	None	----------	----------	----------
Family History	CAD ☐	Diabetes ☒ Mother	Auto immune disease ☐	Others:
Surgical History:	Inguinal Hernia Repair			
Comments:	Mitral valve prolapse, neurofibromatosis, (DX-skin biopsy in late 30's) developmental delay			

HEMODYNAMIC PROFILE

Average BP During Hospitalization (mmHg)	130/80	
Average Low BP During Hospitalization (mmHg)	88/61	**Duration: 5 mins.**
Average BP in OR (mmHg)	116/60	
Average Low BP in OR (mmHg)	78/34	**Duration**: 1 min.
Average HR in OR (bpm)	90	
ABG-pH range	(Pre-Op, 7.19 – 7.48), (Intra-Op, 7.32 – 7.36)	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	None	----------	----------
PRBCs	None	----------	----------
Platelets	None	----------	----------
Norepinephrine (Levophed)		6 mcg/min for $\simeq$ 1 hour	
Vasopressin	None		
Neo-Synephrine	None		
Epinephrine	None		
Phenylephrine	None		
Dopamine	None		

HPAP006 Donor Summary

Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	None	----------	----------
PRBCs	None	----------	----------
Platelets	None	----------	----------
Norepinephrine (Levophed)	None	----------	----------
Vasopressin	None	----------	----------
Neo-Synephrine (phenylephrine)		100 mcg/min	
Epinephrine	None	----------	----------
Dopamine	None	----------	----------
Heparin		20,000	

Initial Autoantibody Screening (nPOD):

GAD-65	IA-2
Negative	Negative

Confirmatory results (University of Florida) *

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)	C-peptide (ng/ml)	Proinsulin
Results	0	0	-0.003	0.001	6.58	ND
Cut-off values	20	5	0.010	0.020	----------	ND

*Sample obtained at time of organ recovery

HLA (OPO) *

Class 1	**A**	24	25	**Class II**	**DR**	11	13
	B	62	18		**DR51**	Negative	
	C	9	12		**DR52**	Positive	
	Bw4	Negative			**DR53**	Negative	
	Bw6	Positive			**DQB**	7	6
					DQA	01	05
					DPB	02:01	04:01

*HLA typing performed by Methodology RT – PCR

Confirmatory HLA (UPENN)*

Class 1	**A**	24	25	**Class II**	**DRB**	11	13
	B	62	18		**DRB3/4/5**	52	----------
	C	W9	12		**DQ**	7	6
	BW	6	----------		**DQA1**	01	05
					DPB1	02:01	04:01
					DPA1	01	----------

*HLA typing performed using RT-PCR

HPAP006 Donor Summary

Confirmatory HLA (UPENN) *

Class 1	**A**	24:02	25:01		**DRB1**	11:03	13:01
	B	15:01	18:01	**Class II**	**DRB3**	01:01	02:02
	C	03:03	12:03		**DRB4**	----------	----------
					DRB5	----------	----------
					DQB1	03:01	06:03
					DQA1	01:03	05:05
					DPB1	02:01	04:01
					DPA1	01:03	----------

***Performed by Next Generation Sequencing (NGS)**

Infectious Disease Serology

Test	**Result**	**Hemo/Plasma Dilution Status**	
		Qualified	**Non-Qualified**
EBV IgG	Negative	Yes	
EBV IgM	Negative	Yes	
CMV	Positive	Yes	
HBcAb	Non-Reactive	Yes	
HBsAg	Non-Reactive	Yes	
HCV Ab	Non-Reactive	Yes	
HIV I/II	Non-Reactive	Yes	
Syphilis	Non-Reactive	Yes	
Procleix Ultrio	----------	----------	
Ultrio HBV	Non-Reactive	Yes	
Ultrio HCV	Non-Reactive	Yes	
Ultrio HIV	Non0Reactive	Yes	
Toxoplasma IgG	Negative	Yes	

Laboratory Panel

	Initial	**Peak**	**Terminal**
Na (mEq/L) (135-145)			169
Creatinine (<1.5)	0.9	1.0	0.9
Glucose (65-159)	144	242	242
HbA1C%	5.3	----------	----------
Total bilirubin (0-1.0)	0.6	0.6	0.3
SGOT (AST) (0-40)	15	16	16
SGPT (ALT) (u/L)	18	18	14
Alkaline phosphatase (45-110)	ND	ND	ND
Serum Amylase (23-851)	43	47	43
Serum Lipase (0-80)	10	10	8
WBC (THO/uL)	17.3	28.1	26.3
Hgb (g/dL)	17.3	17.3	13.5
Platelets (THO/uL)	270	270	211
INR	1.02	1.44	1.44

Urinalysis

	1st	2nd	3rd	
Glucose	ND	ND	250	

Medications During Hospitalization

Steroids **	Solumedrol 1 gm before OR		
Diuretics	Mannitol in OR		
T3 Protocol	None		
T4 Protocol*	Yes – 40 mcg/hr continued in OR		
Insulin**	None		
Antihypertensive	None		
Vasodilators	None		
DDAVP**	None		
Total parenteral nutrition	None		
Other		Specify	

***T4 protocol**: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.

**** Excluding T4 Protocol**